| First Author | Rios-Arce ND | Year | 2020 |
| Journal | J Cell Physiol | Volume | 235 |
| Issue | 3 | Pages | 2350-2365 |
| PubMed ID | 31538345 | Mgi Jnum | J:299897 |
| Mgi Id | MGI:6490792 | Doi | 10.1002/jcp.29141 |
| Citation | Rios-Arce ND, et al. (2020) Loss of interleukin-10 exacerbates early Type-1 diabetes-induced bone loss. J Cell Physiol 235(3):2350-2365 |
| abstractText | Type-1 diabetes (T1D) increases systemic inflammation, bone loss, and risk for bone fractures. Levels of the anti-inflammatory cytokine interleukin-10 (IL-10) are decreased in T1D, however their role in T1D-induced osteoporosis is unknown. To address this, diabetes was induced in male IL-10 knockout (KO) and wild-type (WT) mice. Analyses of femur and vertebral trabecular bone volume fraction identified bone loss in T1D-WT mice at 4 and 12 weeks, which in T1D-IL-10-KO mice was further reduced at 4 weeks but not 12 weeks. IL-10 deficiency also increased the negative effects of T1D on cortical bone. Osteoblast marker osterix was decreased, while osteoclast markers were unchanged, suggesting that IL-10 promotes anabolic processes. MC3T3-E1 osteoblasts cultured under high glucose conditions displayed a decrease in osterix which was prevented by addition of IL-10. Taken together, our results suggest that IL-10 is important for promoting osteoblast maturation and reducing bone loss during early stages of T1D. |
